RxDoctor Payments Data

Rori Bridges

Family · Forest, MSNPI 1114170529

Payments from drug & device makers

$892in general payments, 2019–2025

Across 59 payments — averaging $15.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$100
  • Lilly USA, LLC$98
  • AstraZeneca$88
  • AbbVie$86
  • Novo Nordisk$74
  • Sumitomo Pharma America, Inc.$60
  • plus $385 from 14 others

What the payments were for

  • Food & beverage$892100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$892 in reported general payments places this provider in the 65th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$22,394
Medicare patients
90
Services billed
350

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron59$35,333
MyrbetriqMirabegron17$13,886
Estradiol41$1,560
Cefdinir18$238
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst16$187
Fluconazole23$125
Metronidazole15$89
Oxybutynin Chloride ErOxybutynin Chloride14$70
Cephalexin12$64

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$60$35,33359 claims
Astellas Pharma US IncMyrbetriq$50$13,88617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,007 family providers in Mississippi.

Other family in Forest

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →